Keros Therapeutics (NASDAQ:KROS) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Keros Therapeutics (NASDAQ:KROS) from a sell rating to a strong sell rating in a research note released on Saturday morning,Wall Street Zen reports.

KROS has been the topic of several other research reports. Leerink Partners lowered their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Wells Fargo & Company dropped their target price on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 4th. Zacks Research raised Keros Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Keros Therapeutics in a report on Tuesday, August 4th. Four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Keros Therapeutics has an average rating of “Hold” and an average target price of $20.50.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $11.32 on Friday. The company has a market capitalization of $224.48 million, a P/E ratio of -3.06 and a beta of 1.01. The company has a 50 day simple moving average of $10.82 and a 200-day simple moving average of $11.33. Keros Therapeutics has a 1 year low of $9.69 and a 1 year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, research analysts expect that Keros Therapeutics will post -5.27 EPS for the current year.

Insider Buying and Selling

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the sale, the insider owned 27,559 shares in the company, valued at $283,582.11. This trade represents a 11.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 5,893 shares of company stock valued at $60,507 over the last ninety days. Corporate insiders own 12.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd lifted its stake in Keros Therapeutics by 254.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after acquiring an additional 1,166 shares in the last quarter. California State Teachers Retirement System increased its holdings in shares of Keros Therapeutics by 72.6% in the 2nd quarter. California State Teachers Retirement System now owns 2,729 shares of the company’s stock valued at $29,000 after purchasing an additional 1,148 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares during the period. Legal & General Group Plc purchased a new stake in shares of Keros Therapeutics in the second quarter worth approximately $90,000. Finally, XTX Topco Ltd acquired a new stake in shares of Keros Therapeutics during the fourth quarter worth approximately $212,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.